Literature DB >> 2288550

The incidence of retinoblastoma in the United States: 1974 through 1985.

A Tamboli1, M J Podgor, J W Horm.   

Abstract

We have estimated the incidence of retinoblastoma in the United States from data available form the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, Bethesda, Md (1974 through 1985). The larger number of cases available (220) compared with those of previous US population-based studies enabled us to evaluate change in incidence over time and to more precisely estimate incidence according to various demographic characteristics. The incidence of retinoblastoma has been almost uniform form 1974 to 1985. The average annual incidence of retinoblastoma was 5.8 per million for children younger than 10 years and 10.9 per million for children younger than 5 years. There was no difference in the incidence of retinoblastoma by either sex or race. The overall 5-year cumulative survival rate was 91% (95% confidence interval, 87% to 95%). The data indicate a worsening survival with increasing age at diagnosis, through age 2 years, but a less clear relationship of survival with diagnosis beyond age 2 years.

Entities:  

Mesh:

Year:  1990        PMID: 2288550     DOI: 10.1001/archopht.1990.01070030134045

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  35 in total

1.  Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma.

Authors:  H Z Noorani; H N Khan; B L Gallie; A S Detsky
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

2.  The Asian Grocery Store-Based Cancer Education Program: Creating New Education Modules.

Authors:  Linh Truong; John Tat; Molly Booy; Annie Le; Jeanne Marie Marasigan; Christine Yuan; Athena Zeng; Anand Panchal; Georgia Robins Sadler
Journal:  J Cancer Educ       Date:  2016-06       Impact factor: 2.037

3.  Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Christina Decatur; Timothy G Murray; Samuel K Houston; Milena Lopez-Cavalcante; Eleut Hernandez; Magda Celdran; Nikesh Shah; William Feuer; Theodore Lampidis
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-27       Impact factor: 4.799

4.  Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Authors:  Samuel K Houston; Yolanda Pina; Jennifer Clarke; Tulay Koru-Sengul; William K Scott; Lubov Nathanson; Amy C Schefler; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

5.  Eye cancer incidence in Singapore.

Authors:  S B Lee; K G Au Eong; S M Saw; T K Chan; H P Lee
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

6.  Retinoblastoma. Continuum of care.

Authors:  J N Simmons; M A Zabrycki
Journal:  Can Fam Physician       Date:  1993-06       Impact factor: 3.275

Review 7.  Recent advances in the gene map of inherited eye disorders: primary hereditary diseases of the retina, choroid, and vitreous.

Authors:  P J Rosenfeld; V A McKusick; J S Amberger; T P Dryja
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

8.  Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.

Authors:  Yolanda Piña; Hinda Boutrid; Timothy G Murray; Martine J Jager; Colleen M Cebulla; Amy Schefler; Long V Ly; Armando Alegret; Magda Celdran; William Feuer; Maria-Elena Jockovich
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

9.  Calcification of scleral-wrapped orbital implant in patients with retinoblastoma.

Authors:  C G Summers
Journal:  Pediatr Radiol       Date:  1993

10.  Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: a potential role for the canonical Wnt signaling pathway.

Authors:  Amanda K Silva; Hyun Yi; Sarah H Hayes; Gail M Seigel; Abigail S Hackam
Journal:  Mol Vis       Date:  2010-01-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.